Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00258999 · ClinicalTrials.gov registry record · NA

Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study

A NA study, sponsored by University of Wisconsin, Madison.

Completed
Registry status
NA
Development phase
600
Enrollment target

NCT00258999: Completed NA study, sponsored by University of Wisconsin, Madison.

NCT00258999 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 600 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00258999, a NA study, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
NA
Development phase
600 participants
Enrollment target

Study Summary

The study will evaluate the clinical utilization of skin Cholesterol (SC) for cardiovascular risk assessment in asymptomatic individuals at low, intermediate and high risk based on Framingham global risk estimates. Preliminary studies have suggested that SC is an easy to measure, noninvasive marker of cardiovascular risk. This study is intended to provide further data in support of broader clearance by the Food and Drug Administration for the use of SC as a tool to identify asymptomatic patients at increased risk of cardiovascular disease. Currently, SC testing is cleared for use as part of risk assessment in subject suspected of having significant multi-vessel disease. The current study data will be used to support the use of SC testing as part of cardiovascular risk assessment in subjects without suspected coronary artery disease (CAD).

Interventions

  • DEVICE Skin Cholesterol Testing

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2005-10
Est. Completion 2007-11
Phase NA
University of Wisconsin, Madison

1,039 total trials

What the finished NCT00258999 record still lists

NCT00258999 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower).

The record links to 0 conditions, and to 1 intervention - of which Skin Cholesterol Testing is the first listed.

NCT00258999 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00258999 about?

NCT00258999 is a clinical study titled "Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study". The study will evaluate the clinical utilization of skin Cholesterol (SC) for cardiovascular risk assessment in asymptomatic individuals at low, intermediate and high risk based on Framingham global risk estimates. Preliminary studies have suggested that SC is an easy to measure, noninvasive marker...

What is the current status of trial NCT00258999?

This trial is currently completed. It is a NA study. The enrollment target is 600 participants. The study started on 2005-10. Estimated completion is 2007-11.

What interventions are being tested in trial NCT00258999?

The interventions under investigation include: Skin Cholesterol Testing (DEVICE).

Who is sponsoring clinical trial NCT00258999?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00258999's enrollment target sits among peer trials

600 162nd of 2000 higher than 1,827 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00258999, the US trial registry maintained by the National Library of Medicine. NCT00258999 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.